Ana-marija Grisic

Frankfurter Str. 250
Darmstadt, HE 64293, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Variable or variate? A conundrum in pharmacometrics exposure-response models.

Variable or variate? A conundrum in pharmacometrics exposure-response models.

Journal: CPT: pharmacometrics & systems pharmacology

Published: September 28, 2022

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.

Journal: Cancer chemotherapy and pharmacology

Published: April 05, 2022

Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors.

Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors.

Journal: Clinical pharmacokinetics

Published: February 02, 2022

Pharmacometrics Golems: Exposure-Response Models in Oncology.

Pharmacometrics Golems: Exposure-Response Models in Oncology.

Journal: Clinical pharmacology and therapeutics

Published: December 21, 2021

Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.

Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 19, 2021

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.

Journal: United European gastroenterology journal

Published: July 05, 2020

Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management.

Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management.

Journal: British journal of clinical pharmacology

Published: June 06, 2020

Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study.

Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study.

Journal: CPT: pharmacometrics & systems pharmacology

Published: January 28, 2020

Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.

Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.

Journal: Therapeutic drug monitoring

Published: March 19, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026